D. E. Shaw & Co., Inc. Alnylam Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 332,305 shares of ALNY stock, worth $80.8 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

332,305

Holding current value

$80.8 Million

% of portfolio

0.09%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$233.81 - $287.01 $12.4 Million - $15.2 Million	52,907 Added 18.94%	332,305 $91.4 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $25.2 Million - $43.5 Million	176,011 Added 170.24%	279,398 $67.9 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $1.15 Million - $1.55 Million	7,843 Added 8.21%	103,387 $15.5 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $16.4 Million - $21.3 Million	-108,548 Reduced 53.19%	95,544 $18.3 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $7.54 Million - $9.35 Million	-44,180 Reduced 17.79%	204,092 $36.1 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $3.13 Million - $3.59 Million	16,927 Added 7.32%	248,272 $47.2 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $10 Million - $12.9 Million	54,929 Added 31.14%	231,345 $46.3 Million
Q4 2022 Feb 14, 2023	BUY	$185.53 - $241.31 $4.69 Million - $6.1 Million	25,272 Added 16.72%	176,416 $41.9 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $2.11 Million - $3.53 Million	15,221 Added 11.2%	151,144 $30.3 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $14.6 Million - $20.5 Million	121,040 Added 813.28%	135,923 $19.8 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $4 Million - $5.47 Million	-31,457 Reduced 67.88%	14,883 $2.43 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $2.12 Million - $2.78 Million	13,277 Added 40.16%	46,340 $7.86 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $567,813 - $694,856	-3,345 Reduced 9.19%	33,063 $6.24 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $5.34 Million - $7.34 Million	-41,495 Reduced 53.26%	36,408 $6.17 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $1.7 Million - $2.35 Million	13,402 Added 20.78%	77,903 $11 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $13 Million - $15.5 Million	-105,737 Reduced 62.11%	64,501 $8.38 Million
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $6.83 Million - $9.33 Million	56,351 Added 49.48%	170,238 $24.8 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $12.2 Million - $18.3 Million	-116,666 Reduced 50.6%	113,887 $16.9 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $19.7 Million - $28.4 Million	211,925 Added 1137.67%	230,553 $25.1 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $608,672 - $1.01 Million	-8,169 Reduced 30.48%	18,628 $2.15 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $924,536 - $1.15 Million	13,040 Added 94.79%	26,797 $2.16 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $167,481 - $235,964	2,543 Added 22.68%	13,757 $998,000
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $1.86 Million - $2.39 Million	-25,604 Reduced 69.54%	11,214 $1.05 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $1.76 Million - $2.48 Million	28,080 Added 321.36%	36,818 $2.68 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $6.55 Million - $9.18 Million	-74,873 Reduced 89.55%	8,738 $765,000
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $16.6 Million - $20.2 Million	-187,450 Reduced 69.15%	83,611 $8.24 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $192,311 - $246,427	-1,659 Reduced 0.61%	271,061 $32.3 Million
Q4 2017 Feb 14, 2018	SELL	$114.49 - $139.98 $81.3 Million - $99.3 Million	-709,734 Reduced 72.24%	272,720 $34.6 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $71.3 Million - $116 Million	982,454	982,454 $115 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account